Mounjaro®
Starting from £179.99/mo
Start journey Learn moreTaking weight loss injections alongside ADHD medication is a question that comes up regularly in clinical practice, and the honest answer is nuanced. GLP-1 medicines such as tirzepatide (Mounjaro) and semaglutide (Wegovy) can reduce appetite significantly, which matters when ADHD stimulant medications are already known to suppress hunger. Both are prescription-only medicines requiring individual clinical assessment before any treatment begins. The interaction picture is not simple, and a prescriber who knows your full medication list needs to review it carefully before anything is started or changed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide and semaglutide both slow the rate at which the stomach empties its contents into the small intestine. That is part of how they reduce appetite. For most medicines, a modest delay in gastric emptying has little clinical consequence. ADHD stimulants are a different conversation.
Immediate-release methylphenidate and lisdexamfetamine rely partly on relatively predictable absorption timing. If gastric emptying is meaningfully slowed, the peak plasma concentration of the ADHD medicine may shift, arriving later or with a flatter curve than expected. The practical result could be that the medication feels less effective in the morning and then kicks in more strongly later in the day, disrupting the timing that has been carefully established.
This does not mean the two cannot be used together. It means the prescriber needs to know. Patients who notice their ADHD medication behaving differently after starting a GLP-1 injection should flag it promptly rather than adjust doses themselves. The NHS patient information for tirzepatide is a useful starting point, but a prescriber familiar with your full regimen is the right person to assess any change. You can explore how the injections work in more detail on our weight loss medication injection overview.
A question our prescribers hear most weeks is some version of: "I'm already not very hungry on my ADHD meds — will Mounjaro make that worse?" The short answer is: it can, and it warrants attention.
Stimulant medications suppress appetite as a known side effect. Tirzepatide and semaglutide reduce hunger through GIP and GLP-1 receptor pathways. Stack those effects and some people find they are eating very little, skipping meals without noticing, and losing muscle mass alongside fat. That is not a harmless shortcut. Protein adequacy, hydration and maintaining enough caloric intake to sustain energy and brain function all matter — particularly when concentration is already being managed through medication.
Under-eating can also affect ADHD medication performance. Blood glucose fluctuations from skipped meals interact with cognitive performance in ways that make ADHD symptoms harder to manage. Practical strategies (eating a small protein-containing breakfast before the ADHD medication fully kicks in, setting phone reminders for lunch) are worth discussing with a prescriber or dietitian. The dedicated ADHD and weight loss injections page covers this territory in more depth.
Most ADHD medicines prescribed in the UK fall into one of two categories: stimulants (methylphenidate-based products such as Ritalin and Concerta, and lisdexamfetamine, sold as Vyvanse) and non-stimulants (atomoxetine, guanfacine). The appetite and absorption questions above apply most clearly to the stimulant group.
Atomoxetine, a non-stimulant, has a different absorption profile and a different side-effect pattern. It does not suppress appetite in the same way, so the double-suppression concern is lower. That said, it carries its own cardiovascular monitoring requirements, and GLP-1 medicines have effects on heart rate that a prescriber will factor into the review.
Guanfacine works differently again, primarily affecting blood pressure regulation. Any medicine that influences blood pressure warrants careful co-prescribing assessment. None of this amounts to a hard rule that combination is always fine or always contraindicated, it is precisely the kind of individual assessment a GPhC-registered prescriber carries out. For context on the full range of injection medicine names licensed in the UK, that page sets out what is available and on what basis.
Completeness is the most useful thing you can bring to a consultation. That means listing every medicine you take, including any that are prescribed by a different specialist, anything taken intermittently, and any supplements. ADHD medication in particular is relevant because of the absorption and appetite dynamics above.
It also helps to describe your current eating pattern honestly. If you are already eating less than you should because of stimulant-related appetite suppression, a prescriber needs that information to judge whether adding a GLP-1 medicine is appropriate and at what pace titration should proceed.
If you are considering weight loss treatment options more broadly, our weight management overview covers both injection and non-injection routes, and those curious about the best non-injection weight loss medication will find a detailed comparison of the tablet and oral options currently available. Our FAQs address many of the practical concerns people raise before their first consultation. Those who prefer to understand the injection technique side of things will find the injection guide helpful once treatment is confirmed as suitable. For an overview of current weight loss injection pricing in the UK, that page explains what legitimate private treatment typically includes.
At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber on the same day it is submitted. If your ADHD medication list raises any questions, the prescriber addresses them directly before any decision is made. Start your free consultation to have your full medication picture reviewed.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.